[144] Vor Biopharma Inc. SEC Filing

Rhea-AI Filing Summary

Vor Biopharma Inc. Form 144 notifies the market that a person identified as Audrey Skillern intends to sell 23,000,000 common shares on or about 09/03/2025 on NASDAQ. The filing lists an aggregate market value of $46,115,000 for the shares and reports 126,683,111 shares outstanding for the issuer.

The shares were acquired from the company in a private placement on 12/26/2024 and fully paid in cash on that date. The filer reports no securities sold in the past three months. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

• Full disclosure of the intended sale including share count, aggregate value, acquisition date, and payment method
• No sales in the prior three months reported for the account, reducing ambiguity about recent insider activity

Negative

• Large block of 23,000,000 shares proposed for sale, which could increase available float relative to 126,683,111 shares outstanding
• Sale date set (09/03/2025) indicating a near-term potential increase in market supply

Insights

Financial Analyst

TL;DR: A sizable block of newly issued shares is scheduled for sale, which could increase float and supply.

The filing discloses an intention to sell 23,000,000 common shares acquired in a company private placement dated 12/26/2024, with an aggregate market value reported at $46,115,000 and 126,683,111 shares outstanding. This is a material disclosure for investors because it signals potential additional supply hitting the market on or about 09/03/2025. The filer also states there were no sales in the prior three months and that payment was made in cash, which clarifies the acquisition was a straightforward private issuance.

Corporate Governance Expert

TL;DR: The Form 144 meets disclosure requirements and includes the seller's representation regarding undisclosed material information.

The document provides required details: holder identity, acquisition method (private placement from the company), acquisition and payment dates, and intent to sell on NASDAQ. The signature/representation language attests the seller is not aware of undisclosed material adverse information. There is no information about any trading plan or restrictions beyond the stated dates, and no prior three-month sales were reported.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Audrey skillern 805 saint johns dr mansfield tx 76063 Mansfield TX 76063	23000000	46115000.00	126683111	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/26/2024	Private Placement	Company			23000000	12/26/2024	cash/check

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Vor Biopharma's (VOR) Form 144 disclose?

The filing discloses an intent to sell 23,000,000 common shares on or about 09/03/2025 on NASDAQ, with aggregate market value of $46,115,000 and 126,683,111 shares outstanding.

Who acquired the shares to be sold according to the filing?

The filing shows the shares were acquired by the seller via a private placement from the company on 12/26/2024 and paid in cash on that date.

Did the filer report any sales of Vor (VOR) shares in the past three months?

No. The section for securities sold during the past three months states Nothing to Report.

On which exchange does the Form 144 state the shares will be sold?

The filing lists NASDAQ as the securities exchange where the proposed sale will occur.

What representation does the seller make in the Form 144?

The seller represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.